Theratechnologies Inc T.TH

Alternate Symbol(s): THTX

Healthcare Biotechnology

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.

TSX:TH - Post by User

Theratechnologies Inc > Novel Format Conjugates February 2023

<< Previous

Bullboard Posts

Next >>

Comment by qwerty22on Oct 21, 2022 12:29pm

97 Views

Post# 35039229

RE:RE:RE:Novel Format Conjugates February 2023

I wondered about that but it's probably preclinical, like the paper they just published that was largely about engaging Sortilin.

Wino115 wrote: It's interesting that, if accurate, the wording seems to also suggst a bit more detail on some of the MOA issues. Maybe it's just all the 2 years of studying it, but perhaps they'd be more inclined to discuss the detailed science PK/PD data learned in 1a and 1b in that kind of setting. Maybe the "validation" is both pre-clinical and some of what they've seen so far.

"...validation of the unique MoA and kinetics of internalization of TH1902 into the cancer cells..."

qwerty22 wrote:
"Gain insight into the status of the Phase I Study"

Erm, yes please!

scarlet1967 wrote: https://next-gen-conjugates.com/speaker/christian-marsolais/